Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach US$ 1.42 Billion by 2035, Driven by Rising Adoption of Complement Inhibitors

The global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market was valued at USD 0.87 billion in 2025 and is projected to reach USD 1.42 billion by 2035, growing at a CAGR of 6.02% during the forecast period from 2025 to 2035. The market is gaining importance with the growing recognition of aHUS as a rare, potentially life-threatening complement-mediated disorder that can cause thrombotic microangiopathy, kidney damage, anemia, and thrombocytopenia. The treatment landscape is increasingly centered on complement inhibitors, which have shifted care from conventional plasma exchange and supportive management toward targeted therapies. The emergence of biosimilar options is also creating opportunities to improve treatment accessibility and potentially reshape the competitive landscape.

The market's most significant opportunity lies in targeted complement pathway therapies and next-generation treatment approaches. Complement inhibitors remain a key commercial segment, while pharmaceutical companies are exploring therapies designed to provide more convenient administration, sustained complement control, and improved patient outcomes. Amgen's Bkemv, approved by the U.S. FDA in 2024 as the first interchangeable biosimilar to Soliris for aHUS and PNH, represents an important development that could expand treatment options and introduce greater competition in the complement-inhibitor space. As diagnosis improves and access to specialized nephrology care expands, investment in rare-disease therapeutics, complement-targeted drugs, and patient-support programs is expected to remain central to the evolution of the aHUS treatment market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/atypical-hemolytic-uremic-syndrome-treatment-market?sai-v

Recent Developments
July 2026: AstraZeneca continued expanding access to ULTOMIRIS (ravulizumab) for aHUS across major markets, supporting long-acting C5 complement inhibition for adult and pediatric patients. The therapy remains an important treatment option for complement-mediated thrombotic microangiopathy in aHUS.

June 2026: Novartis continued clinical development of iptacopan (Fabhalta) for aHUS, advancing an oral factor B inhibitor approach designed to target the alternative complement pathway. The program reflects growing interest in oral complement therapies that could provide an alternative to currently available intravenous complement inhibitors.

May 2026: AstraZeneca strengthened its complement-mediated disease portfolio around ULTOMIRIS, with the therapy continuing to serve patients with aHUS in North America, Europe, Japan, and other markets. The broad geographic availability supports increasing adoption of complement inhibition as a core approach to controlling complement-mediated TMA.

April 2026: Novartis advanced its rare kidney disease strategy through continued investigation of Fabhalta (iptacopan) in aHUS and other complement-mediated renal diseases. The company's development strategy is expanding beyond its approved kidney indications toward additional diseases where alternative-pathway complement activation plays a central role.

March 2026: Complement-targeted therapies continued to shape the aHUS treatment landscape, with established C5 inhibitors such as eculizumab and ravulizumab remaining central to disease management while next-generation therapies targeting earlier components of the alternative pathway advance through clinical development. This is driving competition around oral administration, dosing convenience, sustained complement control, and broader patient access.

Key Players
Alexion Pharmaceuticals, Inc. | AstraZeneca Plc | Novartis AG | Omeros Corporation | Chugai Pharmaceutical Co., Ltd. | GNH India | Bio-Rad Laboratories, Inc. | Others

Key Highlights
Alexion Pharmaceuticals, Inc. - Holds a 38.5% share, driven by its leadership in complement-mediated rare disease therapies, particularly C5 complement inhibition for atypical hemolytic uremic syndrome (aHUS).

AstraZeneca Plc - Holds a 18.7% share, supported by its rare disease portfolio, complement biology expertise, and integration of Alexion's specialized aHUS treatment capabilities.

Novartis AG - Holds a 14.6% share, strengthened by its innovative immunology and rare disease portfolio, complement pathway research, and development of next-generation targeted therapies.

Omeros Corporation - Holds a 10.2% share, fueled by its MASP-2 inhibition platform and development of complement-targeted therapies for diseases involving the lectin pathway.

Chugai Pharmaceutical Co., Ltd. - Holds a 7.4% share, driven by its antibody engineering capabilities, complement pathway research, and innovative biologics development for rare and immune-mediated diseases.

GNH India - Holds a 5.1% share, supported by its specialized pharmaceutical and healthcare services, rare disease treatment access, and diagnostic and therapeutic support capabilities.

Bio-Rad Laboratories, Inc. - Holds a 3.2% share, strengthened by its diagnostic technologies, immunohematology solutions, laboratory testing platforms, and tools supporting rare disease diagnosis.

Others - Hold a combined 2.3% share, comprising emerging biotechnology companies, complement-targeted therapy developers, diagnostic providers, and specialty pharmaceutical firms working on innovative aHUS treatment approaches.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=atypical-hemolytic-uremic-syndrome-treatment-market?sai-v

Market Drivers
Rising diagnosis of rare complement-mediated disorders, increasing awareness of aHUS, and growing availability of genetic and complement testing are driving market growth.

Increasing adoption of complement inhibitors such as eculizumab and ravulizumab is accelerating demand for targeted aHUS treatment.

Advancements in complement-pathway therapies, genetic diagnostics, and personalized treatment approaches are improving disease management.

Market Opportunities
Growing demand for next-generation complement inhibitors and longer-acting therapies is creating new opportunities.

Increasing investments in rare-disease diagnostics, genetic testing, and complement-targeted drug development are expanding market potential.

Development of subcutaneous and oral therapies could improve treatment convenience and broaden patient access.

Strategic collaborations between pharmaceutical companies, biotechnology firms, and rare-disease research organizations are supporting pipeline development.

Industry Developments
Complement inhibitors, precision diagnostics, and next-generation targeted therapies are transforming the aHUS treatment landscape.

Expanded genetic testing and complement-pathway diagnostics are supporting earlier identification and treatment of aHUS patients.

The FDA approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris for aHUS and PNH, increasing treatment competition.

Clinical research, biosimilar development, regulatory activity, and new complement-targeting therapies are strengthening the competitive landscape.

Regional Insights
North America 40.6% share: Leads the market due to advanced rare-disease diagnosis, strong healthcare infrastructure, high adoption of complement inhibitors, and significant pharmaceutical R&D.

Europe 29.2% share: Growth is supported by established rare-disease programs, increasing genetic testing, specialist nephrology services, and adoption of targeted therapies.

Asia Pacific 23.1% share: Fastest-growing region, driven by improving rare-disease diagnosis, expanding healthcare infrastructure, increasing awareness, and growing pharmaceutical investments.

Latin America 4.0% share: Supported by improving access to specialized nephrology care, expanding diagnostic capabilities, and rising awareness of aHUS.

Middle East & Africa 3.1% share: Driven by healthcare modernization, improving rare-disease diagnosis, and increasing access to advanced complement-targeted treatments.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/atypical-hemolytic-uremic-syndrome-treatment-market?sai-v

Key Segments
➥ By Treatment Type

Complement Inhibitors: Represents the dominant segment, driven by the effectiveness of complement-targeted therapies in controlling uncontrolled complement activation, reducing thrombotic microangiopathy, and improving outcomes for patients with atypical hemolytic uremic syndrome (aHUS).

Supportive Therapy: Represents a significant segment, supported by the use of plasma exchange, plasma infusion, dialysis, blood transfusion, and other supportive interventions for managing complications associated with aHUS.

Others: Represents a growing segment, driven by increasing research into novel complement-targeted therapies, investigational treatments, and emerging approaches aimed at improving long-term disease management.

➥ By End-User

Hospitals: Represents the dominant segment, driven by the need for specialized diagnosis, complement inhibitor administration, intensive monitoring, and management of severe renal and hematological complications.

Specialty Clinics: Represents a significant segment, supported by the growing availability of specialized nephrology and hematology services for long-term management and monitoring of aHUS patients.

Others: Represents a moderate segment, fueled by expanding treatment and monitoring across academic medical centers, research institutions, and specialized rare-disease care facilities.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.